Novartis Partners with Matchpoint for $1 Billion Anti-Inflammatory Drug Development

Swiss pharmaceutical giant Novartis is set to invest up to $1 billion in Matchpoint Therapeutics, a U.S. biotechnology firm, in a deal focused on developing oral medications for various inflammatory diseases. As announced, the collaboration will leverage Matchpoint's proprietary technology to create drugs that inhibit a particular protein to reduce inflammation-causing signals in the body. The agreement includes an upfront payment and research funding of up to $60 million for Matchpoint, with further earnouts tied to reaching specific development and commercial milestones. Should Novartis choose to exclusively license the therapeutic program, it would gain worldwide rights to further develop and commercialize its resulting products, marking a significant step in the global fight against inflammatory health conditions.